Wellington Management Group LLP Increases Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Wellington Management Group LLP grew its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 14.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,243,599 shares of the biopharmaceutical company’s stock after acquiring an additional 1,167,659 shares during the period. Wellington Management Group LLP owned about 0.14% of Celldex Therapeutics worth $314,190,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Celldex Therapeutics in the second quarter valued at about $76,000. KBC Group NV increased its holdings in shares of Celldex Therapeutics by 31.2% in the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares during the last quarter. Los Angeles Capital Management LLC increased its holdings in shares of Celldex Therapeutics by 9.5% in the second quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 638 shares during the last quarter. Quest Partners LLC increased its holdings in shares of Celldex Therapeutics by 1,364.9% in the second quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 6,879 shares during the last quarter. Finally, AQR Capital Management LLC increased its holdings in shares of Celldex Therapeutics by 23.7% in the second quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after purchasing an additional 1,504 shares during the last quarter.

Insider Buying and Selling at Celldex Therapeutics

In other Celldex Therapeutics news, CEO Anthony S. Marucci bought 11,500 shares of the company’s stock in a transaction on Monday, November 11th. The stock was acquired at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the transaction, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This represents a 39.95 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 3.80% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on CLDX shares. Citigroup started coverage on Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 target price on the stock. Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Wednesday, November 20th. Wolfe Research cut Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research note on Monday, September 16th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Price Performance

Shares of NASDAQ CLDX opened at $26.77 on Friday. The business’s 50 day moving average is $27.80 and its two-hundred day moving average is $34.00. Celldex Therapeutics, Inc. has a 1-year low of $22.93 and a 1-year high of $53.18. The stock has a market capitalization of $1.78 billion, a P/E ratio of -10.42 and a beta of 1.57.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.